Literature DB >> 11300764

Protein-DNA binding correlates with structural thermostability for the full-length human p53 protein.

N M Nichols1, K S Matthews.   

Abstract

Full-length p53 protein purified from Escherichia coli in the unmodified, "latent" form was examined by several methods to correlate thermal stability of structure with functional DNA binding. Structure prediction algorithms indicate that the majority of beta-sheet structure occurs in the p53 core DNA binding domain. Circular dichroism spectra demonstrate that the intact protein is surprisingly stable with a midpoint for the irreversible unfolding transition at approximately 73 degrees C. Significant beta-sheet structural signal remains even to 100 degrees C. The persistent beta-sheet CD signal correlates with significant DNA binding (K(d) approximately nM range) to temperatures as high as 50 degrees C. These data confirm the ability of the DNA binding domain in the full-length "latent" protein to bind consensus dsDNA targets effectively in the absence of activators over a broad temperature range. In addition, we demonstrate that Ab1620 reactivity is not directly correlated with the functional activity of the full-length protein since loss of this epitope occurs at temperatures at which significant specific DNA binding can still be measured.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11300764     DOI: 10.1021/bi002088z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  2 in total

1.  The proline rich homeodomain protein PRH/Hhex forms stable oligomers that are highly resistant to denaturation.

Authors:  Anshuman Shukla; Nicholas M Burton; Padma-Sheela Jayaraman; Kevin Gaston
Journal:  PLoS One       Date:  2012-04-23       Impact factor: 3.240

2.  Evaluation of zinc (II) chelators for inhibiting p53-mediated apoptosis.

Authors:  Akinori Morita; Shinya Ariyasu; Soichiro Ohya; Ippei Takahashi; Bing Wang; Kaoru Tanaka; Takatoshi Uchida; Haruna Okazaki; Kengo Hanaya; Atsushi Enomoto; Mitsuru Nenoi; Masahiko Ikekita; Shin Aoki; Yoshio Hosoi
Journal:  Oncotarget       Date:  2013-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.